iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone415-632-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$147.29 million
Profitability
Miscellaneous
Employees748
Next Earnings Date5/7/2019 (Confirmed)
OptionableOptionable
Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions
What is Irhythm Technologies' stock symbol?
Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."
How were Irhythm Technologies' earnings last quarter?
Irhythm Technologies Inc (NASDAQ:IRTC) released its earnings results on Tuesday, February, 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.03. The business earned $43.16 million during the quarter, compared to the consensus estimate of $40.21 million. Irhythm Technologies had a negative net margin of 32.78% and a negative return on equity of 69.79%. The business's revenue was up 53.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.48) earnings per share. View Irhythm Technologies' Earnings History.
When is Irhythm Technologies' next earnings date?
How can I listen to Irhythm Technologies' earnings call?
Irhythm Technologies will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8443480016.
What guidance has Irhythm Technologies issued on next quarter's earnings?
Irhythm Technologies issued an update on its FY 2019 earnings guidance on Tuesday, February, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $201-206 million, compared to the consensus revenue estimate of $194.94 million.
What price target have analysts set for IRTC?
9 Wall Street analysts have issued twelve-month target prices for Irhythm Technologies' shares. Their forecasts range from $75.00 to $110.00. On average, they anticipate Irhythm Technologies' stock price to reach $98.50 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.
What is the consensus analysts' recommendation for Irhythm Technologies?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.
What are Wall Street analysts saying about Irhythm Technologies stock?
Here are some recent quotes from research analysts about Irhythm Technologies stock:
- 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (4/18/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, with revs @ $263M, up 30% y/y. Our rating remains MP, but our PT changes to $75." (2/13/2019)
- 3. BTIG Research analysts commented, "Rise Too; Neutral Q4 revenue was $43.2M, 5% above our estimate in a very strong quarter. Momentum was buoyed by large hospital system penetration, improving sales productivity, and the benefit from cross-selling with ZIO AT. The most positive update was the disclosure that tenured reps are now delivering $2.5M in revenue on average, implying peak productivity continues to trend higher. On initial 2019 expectations, guidance calling for 36-40% revenue growth was above expectations. Management does anticipate a corresponding ~27% increase to the opex base. At this stage of growth and with nearly all in-network contracts in place for XT, we are a little surprised by the amount of spending over and above headcount expansion in areas like algorithms and back-end support. Even so, the company believes there could be a pathway to break-even or even profitability sometime in 2020." (2/13/2019)
Has Irhythm Technologies been receiving favorable news coverage?
News articles about IRTC stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Irhythm Technologies earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Irhythm Technologies' key competitors?
Some companies that are related to Irhythm Technologies include Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Haemonetics (HAE), Novocure (NVCR), Tandem Diabetes Care (TNDM), Merit Medical Systems (MMSI), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO) and Atrion (ATRI).
What other stocks do shareholders of Irhythm Technologies own?
Who are Irhythm Technologies' key executives?
Irhythm Technologies' management team includes the folowing people:
- Mr. Kevin M. King, Pres, CEO & Director (Age 63)
- Mr. Matthew C. Garrett, Chief Financial Officer (Age 51)
- Mr. David A. Vort, Exec. VP of Sales (Age 53)
- Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 46)
- Mr. Karim Karti, Chief Operating Officer (Age 50)
When did Irhythm Technologies IPO?
(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
Who are Irhythm Technologies' major shareholders?
Irhythm Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Pier Capital LLC (0.21%), Los Angeles Capital Management & Equity Research Inc. (0.09%), Columbus Circle Investors (0.05%), Virtu Financial LLC (0.04%), Bailard Inc. (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.
Which institutional investors are selling Irhythm Technologies stock?
IRTC stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC, Columbus Circle Investors and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Irhythm Technologies company stock in the last year include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett and Raymond W Scott. View Insider Buying and Selling for Irhythm Technologies.
Which institutional investors are buying Irhythm Technologies stock?
How do I buy shares of Irhythm Technologies?
Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Irhythm Technologies' stock price today?
One share of IRTC stock can currently be purchased for approximately $74.12.
How big of a company is Irhythm Technologies?
Irhythm Technologies has a market capitalization of $1.81 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.
What is Irhythm Technologies' official website?
How can I contact Irhythm Technologies?
Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]
MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
